Combining bacteriophages with cefiderocol and meropenem/vaborbactam to treat a pan‐drug resistant Achromobacter species infection in a pediatric cystic fibrosis patient. Issue 11 (20th July 2020)
- Record Type:
- Journal Article
- Title:
- Combining bacteriophages with cefiderocol and meropenem/vaborbactam to treat a pan‐drug resistant Achromobacter species infection in a pediatric cystic fibrosis patient. Issue 11 (20th July 2020)
- Main Title:
- Combining bacteriophages with cefiderocol and meropenem/vaborbactam to treat a pan‐drug resistant Achromobacter species infection in a pediatric cystic fibrosis patient
- Authors:
- Gainey, Andrew B.
Burch, Anna‐Kathryn
Brownstein, Michael J.
Brown, David E.
Fackler, Joseph
Horne, Bri'Anna
Biswas, Biswajit
Bivens, Brittany N.
Malagon, Francisco
Daniels, Robert - Abstract:
- Abstract: Cystic fibrosis is associated with significant morbidity and early mortality due to recurrent acute and chronic lung infections. The chronic use of multiple antibiotics without pathogen eradication increases the possibility of extensive drug resistance or even pan‐drug resistance (PDR). It is imperative that new or alternative treatment options be explored. We present a clinical case of a 10‐year‐old female cystic fibrosis patient, infected with a PDR Achromobacter spp. She was treated with cefiderocol, meropenem/vaborbactam, and bacteriophage therapy (Ax2CJ45ϕ2) during two separate admissions in an attempt to clear her infection and restore baseline pulmonary function. The Centers for Disease Control and Prevention confirmed antibiotic susceptibilities, which showed resistance to both cefiderocol and meropenem/vaborbactam. However, after using all three agents concomitantly during the second treatment course, our patient's pulmonary function improved dramatically, and the Achromobacter spp. could not be isolated from sputum samples obtained 8 and 16 weeks after completion of therapy. Overall, the treatment regimen consisting of cefiderocol, meropenem/vaborbactam, and bacteriophage was safe and well‐tolerated in our patient.
- Is Part Of:
- Pediatric pulmonology. Volume 55:Issue 11(2020)
- Journal:
- Pediatric pulmonology
- Issue:
- Volume 55:Issue 11(2020)
- Issue Display:
- Volume 55, Issue 11 (2020)
- Year:
- 2020
- Volume:
- 55
- Issue:
- 11
- Issue Sort Value:
- 2020-0055-0011-0000
- Page Start:
- 2990
- Page End:
- 2994
- Publication Date:
- 2020-07-20
- Subjects:
- achromobacter -- bacteriophage -- cefiderocol -- cystic fibrosis -- meropenem
Pediatric respiratory diseases -- Periodicals
Pediatrics -- Periodicals
618.922 - Journal URLs:
- http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1099-0496 ↗
http://onlinelibrary.wiley.com/ ↗ - DOI:
- 10.1002/ppul.24945 ↗
- Languages:
- English
- ISSNs:
- 8755-6863
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 6417.605800
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 14438.xml